Exchanging hands for $366, the stock is up 33% in 12 months and 16% in 2025. In the first quarter, it reported a revenue of $9.5 billion, up 10% year-over-year, and an EPS of $2.58, up 8% year ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Cramer’s bullish stance was premature as Eli Lilly fell 11.72%. Eli Lilly and Company (NYSE:LLY) remains a leader in obesity and diabetes treatment innovation, with Zepbound driving major growth ...

Eli Lilly and Company (NYSE:LLY) recently announced that Australia’s Therapeutic Goods Administration (TGA) has approved Kisunla (donanemab) for marketing. The drug, administered via intravenous ...

Eli Lilly and Company traded as low as $812.03 and last traded at $821.39. 747,819 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 3,467,154 shares ...

Eli Lilly stock surged as much as 17% after positive phase-three trial data came out for orforglipron. It found orforglipron, a GLP-1 weight-loss pill, led to significant weight and A1C reductions.

Here’s what to know about Eli Lilly’s pill, which still must go through a review process by the Food and Drug Administration to be approved for sale. When will the pill become available?

Eli Lilly and Company (NYSE:LLY – Get Free Report) shares dropped 4.6% on Thursday after Morgan Stanley lowered their price target on the stock from $1,146.00 to $1,124.00.

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth initiatives. Click for my LLY update.

Eli Lilly is partnering with Imagine Entertainment and MACRO to drive industry-wide change and guide in authentically representing disease.

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.